The purpose of this study is to evaluate the efficacy and safety following the Roadmap
Concept strategy with an initial monotherapy using either telbivudine or tenofovir in HBeAg
negative CHB patients. The data from the study should allow for the validation of the
Roadmap concept in a prospective manner, for both telbivudine and tenofovir treated HBeAg
negative CHB patients. As part of a post-approval commitment to the European Health
Authorities, the data will also be used to provide an optimized clinical treatment strategy
for better clinical use of telbivudine in European HBeAg negative patients. Furthermore, the
data from the study will contribute to a better scientific understanding, disease management
and treatment of HBeAg negative CHB patients.
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Novartis Investigative Site, Innsbruck A-6020, Austria; Recruiting
Novartis Investigative Site, Wien 1090, Austria; Recruiting
Novartis Investigative Site, Wien 1160, Austria; Not yet recruiting
Novartis Investigative Site, Sofia 1527, Bulgaria; Recruiting
Novartis Investigative Site, Sofia 1431, Bulgaria; Recruiting
Novartis Investigative Site, Sofia 1407, Bulgaria; Recruiting
Novartis Investigative Site, Sofia 1612, Bulgaria; Recruiting
Novartis Investigative Site, Varna 9010, Bulgaria; Recruiting
Novartis Investigative Site, Düsseldorf 40237, Germany; Not yet recruiting
Novartis Investigative Site, Essen 45147, Germany; Not yet recruiting
Novartis Investigative Site, Frankfurt 60590, Germany; Recruiting
Novartis Investigative Site, Freiburg 79106, Germany; Recruiting
Novartis Investigative Site, Hamburg 20099, Germany; Recruiting
Novartis Investigative Site, Hannover 30625, Germany; Not yet recruiting
Novartis Investigative Site, Heidelberg 69120, Germany; Withdrawn
Novartis Investigative Site, Herne 44623, Germany; Recruiting
Novartis Investigative Site, Köln 50937, Germany; Not yet recruiting
Novartis Investigative Site, Leipzig 04103, Germany; Recruiting
Novartis Investigative Site, Muenchen 81377, Germany; Withdrawn
Novartis Investigative Site, Würzburg 97080, Germany; Recruiting
Novartis Investigative Site, Athens GR 11527, Greece; Recruiting
Novartis Investigative Site, Thessaloniki GR 54636, Greece; Not yet recruiting
Novartis Investigative Site, Palermo 90127, Italy; Withdrawn
Novartis Investigative Site, Moscow 127473, Russian Federation; Recruiting
Novartis Investigative Site, Moscow 119333, Russian Federation; Recruiting
Novartis Investigative Site, Moscow 119992, Russian Federation; Recruiting
Novartis Investigative Site, Moscow 111123, Russian Federation; Recruiting
Novartis Investigative Site, Moscow 129110, Russian Federation; Recruiting
Novartis Investigative Site, Moscow, Russian Federation; Withdrawn
Novartis Investigative Site, Saint-Petersburg 194044, Russian Federation; Recruiting
Novartis Investigative Site, Ankara 06100, Turkey; Withdrawn
Novartis Investigative Site, Ankara 06500, Turkey; Withdrawn
Novartis Investigative Site, Diyarbakir 21280, Turkey; Recruiting
Novartis Investigative Site, Fatih / Istanbul 34098, Turkey; Recruiting
Novartis Investigative Site, Gaziantep 27310, Turkey; Withdrawn
Novartis Investigative Site, Izmir 35040, Turkey; Withdrawn
Novartis Investigative Site, Trabzon 61080, Turkey; Recruiting
Novartis Investigative Site, Malaga, Andalucia 29010, Spain; Withdrawn
Novartis Investigative Site, Caserta, CE 81100, Italy; Terminated
Novartis Investigative Site, Barcelona, Catalunya 08003, Spain; Recruiting
Novartis Investigative Site, Barcelona, Catalunya 08035, Spain; Recruiting
Novartis Investigative Site, Tarragona, Cataluña 43005, Spain; Recruiting
Novartis Investigative Site, Alexandroupolis, GR 68100, Greece; Recruiting
Novartis Investigative Site, Athens, GR 115 21, Greece; Recruiting
Novartis Investigative Site, Thessaloniki, GR 546 39, Greece; Recruiting
Novartis Investigative Site, Majadahonda, Madrid 28222, Spain; Recruiting
Novartis Investigative Site, El Palmar, Murcia 30120, Spain; Withdrawn
Novartis Investigative Site, Padova, PD 35128, Italy; Withdrawn
Novartis Investigative Site, Torino, TO 10126, Italy; Withdrawn